Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer

SIMPLE SUMMARY: The five-year survival rate for advanced biliary tract cancer (BTC) is still less than 10%. Moreover, there is no established second-line chemotherapy after the failure of the first-line chemotherapy. Pembrolizumab is known to be an effective treatment in advanced BTC, but the progno...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Chan Su, Sung, Min Je, Kim, So Jeong, Jo, Jung Hyun, Lee, Hee Seung, Chung, Moon Jae, Bang, Seungmin, Park, Seung Woo, Song, Si Young, Park, Jeong Youp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454917/
https://www.ncbi.nlm.nih.gov/pubmed/36077857
http://dx.doi.org/10.3390/cancers14174323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454917/
https://www.ncbi.nlm.nih.gov/pubmed/36077857
http://dx.doi.org/10.3390/cancers14174323

Ejemplares similares